Picture of Hanmi Pharm logo

128940 — Hanmi Pharm News Story

0.000.00%
kr flag iconLast trade - 00:00
HealthcareSpeculativeLarge CapHigh Flyer

S.Korea's Celltrion falls 7 pct after Temasek sheds some stake

** Shares of Celltrion  068270.KS , South Korea's top
biopharma firm, fall more than 7 pct, after Ion Investments,
which is controlled by Temasek Holdings of Singapore, sells part
of the co's stake on Monday
    ** The block deal, worth of $793 million, was made after 
market close on Monday, and 3.625 million shares were sold by
Tamesek Holdings, according to Credit Suisse which conducted the
transaction 
    ** Each share was traded at 247,000 won ($217.46), down 8
pct from Monday's closing price of 268,500 won, and buyers
included global hedge funds and local institutions, the
investment bank added 
    ** The block deal was oversubscribed, it said
    ** In March, Ion Investment sold up to 2,240,000 shares of
Celltrion, and the pricing represented a discount of 6 to 9 pct
to their pre-deal close  urn:newsml:reuters.com:*:nL4N1QO3TD
    ** Other medical shares drop over the deal, says Kim
Tae-hee, analyst at Mirae Asset Daewoo. Samsung Biologics
 207940.KS  and Hanmi Pharm  128940.KS  fall 4 pct and 2.7 pct,
respectively, while the medical sub-index  .KS32  is down 4.4
pct 
    ** The broader KOSPI market  .KS11  was trading down 1.5 pct
as of 0103 GMT
    
($1 = 1,135.8400 won)

 ((hayoung.choi.thomsonreuters.com@reuters.net
yena.park.thomsonreuters.com@reuters.net))

Recent news on Hanmi Pharm

See all news